Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

Lisa Oestereich, Anja Lüdtke, Stephanie Wurr, Toni Rieger, César Muñoz-Fontela, Stephan Günther

Research output: Contribution to journalArticlepeer-review

407 Scopus citations


Outbreaks of Ebola hemorrhagic fever in sub-Saharan Africa are associated with case fatality rates of up to 90%. Currently, neither a vaccine nor an effective antiviral treatment is available for use in humans. Here, we evaluated the efficacy of the pyrazinecarboxamide derivative T-705 (favipiravir) against Zaire Ebola virus (EBOV) in vitro and in vivo. T-705 suppressed replication of Zaire EBOV in cell culture by 4 log units with an IC90 of 110 μM. Mice lacking the type I interferon receptor (IFNAR-/ -) were used as in vivo model for Zaire EBOV-induced disease. Initiation of T-705 administration at day 6 post infection induced rapid virus clearance, reduced biochemical parameters of disease severity, and prevented a lethal outcome in 100% of the animals. The findings suggest that T-705 is a candidate for treatment of Ebola hemorrhagic fever.

Original languageEnglish
Pages (from-to)17-21
Number of pages5
JournalAntiviral Research
Issue number1
StatePublished - May 2014
Externally publishedYes


  • Antiviral testing
  • Ebolavirus
  • Mouse model


Dive into the research topics of 'Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model'. Together they form a unique fingerprint.

Cite this